<p>在歐洲市場情緒改善的背景下，泛歐 STOXX 歐洲 600 指數在美國與伊朗達成停火協議後顯著上漲 3.05%，增強了該地區投資者的信心。儘管經濟不確定性依然存在，增長預測可能會被下調，各個行業發出的信號也不盡相同，投資者越來越傾向於尋找能夠平衡風險與收益的機會。雖然 “便士股票” 這個術語可能顯得過時，但它仍然指向那些較小或較新的公司，這些公司在強大的財務支持下能夠提供顯著的價值。本文探討了三隻在當今市場環境中因財務韌性和增長潛力而脱穎而出的歐洲便士股票。</p>
<h3>歐洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們歐洲便士股票篩選器中的 277 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Sinteza (BVB:STZ)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Sinteza S.A.是一家羅馬尼亞公司，專注於基本有機化學產品的生產、營銷和銷售，市值為 RON38.21 百萬。</p>
<p><strong>運營：</strong> 公司的收入主要來自其他有機基本化學品的製造，總計為 RON0.39 百萬。</p>
<p><strong>市值：</strong> RON38.21M</p>
<p>Sinteza S.A.是一家羅馬尼亞公司，目前尚未產生收入，銷售額為 RON 0.39 百萬，面臨短期資產為 RON 2.9 百萬無法覆蓋總負債 RON 10.6 百萬的挑戰。儘管處於虧損狀態，該公司已將淨虧損從 RON 8.78 百萬改善至 RON 3.44 百萬，並因每年超過 21% 的自由現金流增長而保持超過三年的現金儲備。Sinteza 無債務，交易價格顯著低於其估計的公允價值，但缺乏經驗豐富的管理數據，並且與行業標準相比，盈利增長面臨波動。</p>
<ul>
<li>解鎖我們對 Sinteza 股票分析的全面見解，查看此財務健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 Sinteza 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis"/></p>
<p>BVB:STZ 財務狀況分析截至 2026 年 4 月</p>
<h2>IDL Diagnostics (OM:IDLDX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> IDL Diagnostics AB (publ) 是一家總部位於瑞典的體外診斷公司，製造和銷售用於腫瘤和細菌疾病的 IVD 測試，市值為 SEK78.32 百萬。</p>
<p><strong>運營：</strong> 公司的收入主要來自其細菌學部門，貢獻 SEK29.58 百萬，其次是腫瘤學部門貢獻 SEK23.46 百萬。</p>
<p><strong>市值：</strong> SEK78.32M</p>
<p>IDL Diagnostics AB 是一家瑞典體外診斷公司，儘管面臨挑戰，但展現出韌性。2025 年報告銷售額為 SEK 53.11 百萬，細菌學部門在收入生成中占主導地位。該公司仍處於虧損狀態，淨虧損為 SEK 12.15 百萬，但在過去五年中每年減少虧損 0.8%，並保持超過三年的強勁現金儲備，沒有債務問題。最近的戰略舉措包括與 concile GmbH 成立合資企業，以擴大其快速測試的市場覆蓋，可能在高管變動期間增強未來的收入來源，因為首席執行官 Anders Hultman 離職。</p>
<ul>
<li>點擊探索我們在 IDL Diagnostics 財務健康報告中的詳細發現。</li>
<li>在我們的增長報告中查看 IDL Diagnostics 的分析師預測。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis"/></p>
<p>OM:IDLDX 債務與股本歷史及分析截至 2026 年 4 月</p>
<h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Dr. Miele Cosmed Group S.A.在波蘭及國際市場上生產和銷售化學及化妝品產品，市值為 PLN246.29 百萬。</p>
<p><strong>運營：</strong> 該公司從化妝品、衞生和家庭化學產品的生產中獲得 PLN501.04 百萬的收入。</p>
<p><strong>市值：</strong> PLN246.29M</p>
<p>Dr. Miele Cosmed Group S.A.展現出財務穩定性，短期資產（PLN144.5M）覆蓋短期（PLN143M）和長期負債（PLN26.4M）。該公司的債務與股本比率在五年內從 28.2% 降低至 19.3%，表明財務健康改善，運營現金流覆蓋 77.3% 的債務義務，儘管最近的盈利增長為負（-32.7%），但現金管理效率良好。然而，利潤率從 7.4% 下降至 4.8%，公司的股本回報率仍然較低，為 9%。該股票的交易價格顯著低於估計的公允價值，可能在這些混合信號中提供投資吸引力。</p>
<ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解 Dr. Miele Cosmed Group 的動態。</li>
<li>通過我們的詳細歷史業績報告評估 Dr. Miele Cosmed Group 的過去業績。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis"/></p>
<p>WSE:DMG 債務與股本歷史及分析截至 2026 年 4 月</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接訪問 277 只歐洲便士股票的完整範圍。</li>
<li>對其他選擇感興趣？發現 10 家在 COVID 後生存並蓬勃發展的公司，它們具備應對特朗普關税的正確要素。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
<p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
<p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
<p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
<p>• 跟蹤您股票的公允價值</p>
<p>免費試用演示投資組合</p>

L6EW

XSER

DJMC

歐洲精選高股利指數 STOXX ETF - First Trust

DJSC

<p>泛歐 STOXX 歐洲 600 指數在美國與伊朗停火後，市場情緒改善，上漲了 3.05%。投資者正在關注便士股票，這些股票代表了具有潛在價值的小型公司。本文重點介紹了三隻歐洲便士股票：Sinteza、IDL Diagnostics 和 Dr. Miele Cosmed Group，儘管面臨挑戰，但它們各自展現了財務韌性。Sinteza 尚未產生收入，但其淨虧損有所改善；IDL Diagnostics 減少了虧損併成立了合資企業；而 Dr. Miele Cosmed Group 儘管利潤率下降，但仍顯示出財務穩定性。鼓勵投資者在當前市場環境中探索這些機會</p>

<p>Amid improving market sentiment in Europe, the pan-European STOXX Europe 600 Index saw a notable rise of 3.05% following a U.S.-Iran ceasefire agreement, boosting investor confidence across the region. As economic uncertainties linger with potential cuts to growth forecasts and mixed signals from various sectors, investors are increasingly seeking opportunities that balance risk and reward. While the term &#34;penny stock&#34; might seem outdated, it still points to smaller or newer companies that can offer significant value when backed by strong financials. This article explores three European penny stocks that stand out for their financial resilience and potential for growth in today's market landscape.</p>
<div class="lb-trans"><p>在歐洲市場情緒改善的背景下，泛歐 STOXX 歐洲 600 指數在美國與伊朗達成停火協議後顯著上漲 3.05%，增強了該地區投資者的信心。儘管經濟不確定性依然存在，增長預測可能會被下調，各個行業發出的信號也不盡相同，投資者越來越傾向於尋找能夠平衡風險與收益的機會。雖然 “便士股票” 這個術語可能顯得過時，但它仍然指向那些較小或較新的公司，這些公司在強大的財務支持下能夠提供顯著的價值。本文探討了三隻在當今市場環境中因財務韌性和增長潛力而脱穎而出的歐洲便士股票。</p>
</div><h3>Top 10 Penny Stocks In Europe</h3>
<div class="lb-trans"><h3>歐洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 View Analysis &gt;</td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Ariston Holding (BIT:ARIS)</td>
<td>€3.922</td>
<td>€1.36B</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Angler Gaming (DB:0QM)</td>
<td>€0.31</td>
<td>€239.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Verkkokauppa.com Oyj (HLSE:VERK)</td>
<td>€3.345</td>
<td>€150.79M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Nurminen Logistics Oyj (HLSE:NLG1V)</td>
<td>€0.878</td>
<td>€70.89M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>High (ENXTPA:HCO)</td>
<td>€3.77</td>
<td>€73.07M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.145</td>
<td>€296.54M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Eniro Group (OM:ENRO)</td>
<td>SEK0.698</td>
<td>SEK508.15M</td>
<td>✅ 1 ⚠️ 4 查看分析 </td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.74</td>
<td>€24.78M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Pharming Group (ENXTAM:PHARM)</td>
<td>€1.453</td>
<td>€1.03B</td>
<td>✅ 5 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 277 stocks from our European Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們歐洲便士股票篩選器中的 277 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Sinteza (BVB:STZ)</h2>
<div class="lb-trans"><h2>Sinteza (BVB:STZ)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Sinteza S.A. is a Romanian company involved in the production, marketing, and sale of basic organic chemical products, with a market capitalization of RON38.21 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Sinteza S.A.是一家羅馬尼亞公司，專注於基本有機化學產品的生產、營銷和銷售，市值為 RON38.21 百萬。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from the manufacture of other organic basic chemicals, totaling RON0.39 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其他有機基本化學品的製造，總計為 RON0.39 百萬。</p>
</div><p><strong>Market Cap:</strong> RON38.21M</p>
<div class="lb-trans"><p><strong>市值：</strong> RON38.21M</p>
</div><p>Sinteza S.A., a Romanian company, remains pre-revenue with sales of RON 0.39 million and faces challenges with short-term assets of RON 2.9 million not covering liabilities totaling RON 10.6 million. Despite being unprofitable, the company has improved its net loss from RON 8.78 million to RON 3.44 million year-over-year and maintains a sufficient cash runway for over three years due to positive free cash flow growth of over 21% annually. Sinteza is debt-free, trading significantly below its estimated fair value, but lacks seasoned management data and faces volatility in earnings growth compared to industry standards.</p>
<div class="lb-trans"><p>Sinteza S.A.是一家羅馬尼亞公司，目前尚未產生收入，銷售額為 RON 0.39 百萬，面臨短期資產為 RON 2.9 百萬無法覆蓋總負債 RON 10.6 百萬的挑戰。儘管處於虧損狀態，該公司已將淨虧損從 RON 8.78 百萬改善至 RON 3.44 百萬，並因每年超過 21% 的自由現金流增長而保持超過三年的現金儲備。Sinteza 無債務，交易價格顯著低於其估計的公允價值，但缺乏經驗豐富的管理數據，並且與行業標準相比，盈利增長面臨波動。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Sinteza stock in this financial health report.</li>
<li>Evaluate Sinteza's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Sinteza 股票分析的全面見解，查看此財務健康報告。</li>
<li>通過訪問我們的歷史表現報告，評估 Sinteza 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/6dab6e8f-d263-4249-8f13-06f27245c0d4/chart/financial-position-analysis"/></p>
<p>BVB:STZ Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>BVB:STZ 財務狀況分析截至 2026 年 4 月</p>
</div><h2>IDL Diagnostics (OM:IDLDX)</h2>
<div class="lb-trans"><h2>IDL Diagnostics (OM:IDLDX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> IDL Diagnostics AB (publ) is a vitro diagnostics company based in Sweden that manufactures and sells IVD tests for oncological and bacterial diseases, with a market cap of SEK78.32 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> IDL Diagnostics AB (publ) 是一家總部位於瑞典的體外診斷公司，製造和銷售用於腫瘤和細菌疾病的 IVD 測試，市值為 SEK78.32 百萬。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its Bacteriology segment, which accounts for SEK29.58 million, followed by the Oncology segment at SEK23.46 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其細菌學部門，貢獻 SEK29.58 百萬，其次是腫瘤學部門貢獻 SEK23.46 百萬。</p>
</div><p><strong>Market Cap:</strong> SEK78.32M</p>
<div class="lb-trans"><p><strong>市值：</strong> SEK78.32M</p>
</div><p>IDL Diagnostics AB, a Swedish in vitro diagnostics company, has shown resilience despite challenges. It reported SEK 53.11 million in sales for 2025, with its Bacteriology segment leading revenue generation. The company remains unprofitable with a net loss of SEK 12.15 million but has managed to reduce losses over the past five years by 0.8% annually and maintains a strong cash runway exceeding three years without debt concerns. Recent strategic moves include forming a joint venture with concile GmbH to expand its market reach for rapid tests, potentially enhancing future revenue streams amidst executive transitions as CEO Anders Hultman departs.</p>
<div class="lb-trans"><p>IDL Diagnostics AB 是一家瑞典體外診斷公司，儘管面臨挑戰，但展現出韌性。2025 年報告銷售額為 SEK 53.11 百萬，細菌學部門在收入生成中占主導地位。該公司仍處於虧損狀態，淨虧損為 SEK 12.15 百萬，但在過去五年中每年減少虧損 0.8%，並保持超過三年的強勁現金儲備，沒有債務問題。最近的戰略舉措包括與 concile GmbH 成立合資企業，以擴大其快速測試的市場覆蓋，可能在高管變動期間增強未來的收入來源，因為首席執行官 Anders Hultman 離職。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in IDL Diagnostics' financial health report.</li>
<li>Explore IDL Diagnostics' analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 IDL Diagnostics 財務健康報告中的詳細發現。</li>
<li>在我們的增長報告中查看 IDL Diagnostics 的分析師預測。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/23e3e2c3-0cb5-463c-a9d4-fc907abbe900/chart/debt-equity-history-analysis"/></p>
<p>OM:IDLDX Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>OM:IDLDX 債務與股本歷史及分析截至 2026 年 4 月</p>
</div><h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
<div class="lb-trans"><h2>Dr. Miele Cosmed Group (WSE:DMG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Dr. Miele Cosmed Group S.A. produces and sells chemical and cosmetic products both in Poland and internationally, with a market cap of PLN246.29 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dr. Miele Cosmed Group S.A.在波蘭及國際市場上生產和銷售化學及化妝品產品，市值為 PLN246.29 百萬。</p>
</div><p><strong>Operations:</strong> The company generates revenue of PLN501.04 million from the production of cosmetic, toilet, and household chemistry products.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從化妝品、衞生和家庭化學產品的生產中獲得 PLN501.04 百萬的收入。</p>
</div><p><strong>Market Cap:</strong> PLN246.29M</p>
<div class="lb-trans"><p><strong>市值：</strong> PLN246.29M</p>
</div><p>Dr. Miele Cosmed Group S.A. demonstrates financial stability with short-term assets (PLN144.5M) covering both short-term (PLN143M) and long-term liabilities (PLN26.4M). The company has reduced its debt to equity ratio from 28.2% to 19.3% over five years, indicating improved financial health, while operating cash flow covers 77.3% of its debt obligations, suggesting efficient cash management despite recent negative earnings growth (-32.7%). However, profit margins have declined from 7.4% to 4.8%, and the company's return on equity remains low at 9%. The stock trades significantly below estimated fair value, potentially offering investment appeal amidst these mixed signals.</p>
<div class="lb-trans"><p>Dr. Miele Cosmed Group S.A.展現出財務穩定性，短期資產（PLN144.5M）覆蓋短期（PLN143M）和長期負債（PLN26.4M）。該公司的債務與股本比率在五年內從 28.2% 降低至 19.3%，表明財務健康改善，運營現金流覆蓋 77.3% 的債務義務，儘管最近的盈利增長為負（-32.7%），但現金管理效率良好。然而，利潤率從 7.4% 下降至 4.8%，公司的股本回報率仍然較低，為 9%。該股票的交易價格顯著低於估計的公允價值，可能在這些混合信號中提供投資吸引力。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of Dr. Miele Cosmed Group.</li>
<li>Assess Dr. Miele Cosmed Group's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解 Dr. Miele Cosmed Group 的動態。</li>
<li>通過我們的詳細歷史業績報告評估 Dr. Miele Cosmed Group 的過去業績。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d836070b-f300-4a22-b868-5c9895e67282/chart/debt-equity-history-analysis"/></p>
<p>WSE:DMG Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>WSE:DMG 債務與股本歷史及分析截至 2026 年 4 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Access the full spectrum of 277 European Penny Stocks by clicking on this link.</li>
<li>Curious About Other Options? Uncover 10 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接訪問 277 只歐洲便士股票的完整範圍。</li>
<li>對其他選擇感興趣？發現 10 家在 COVID 後生存並蓬勃發展的公司，它們具備應對特朗普關税的正確要素。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一個地方管理您的所有股票投資組合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我們為股票投資者創建了 <strong>終極投資組合助手</strong>，<strong>而且是免費的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 連接無限數量的投資組合，並以一種貨幣查看您的總額</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通過電子郵件或手機接收新的警告信號或風險提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟蹤您股票的公允價值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免費試用演示投資組合</p>
</div>

2026 年 4 月值得關注的歐洲低價股